Efficacy and safety of guanabenz acetate treatment for non-alcoholic fatty liver disease: a study protocol for a randomised investigator-initiated phase IIa study

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a metabolic syndrome phenotype in the liver and thus obviously associated with metabolic abnormalities, including insulin resistance-related to hyperglycaemic and hyperlipidaemia. The prevalence of NAFLD is increasing worldwide. However, cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwaki, Michihiro, Kessoku, Takaomi, Tanaka, Kosuke, Ozaki, Anna, Kasai, Yuki, Yamamoto, Atsushi, Takahashi, Kota, Kobayashi, Takashi, Nogami, Asako, Honda, Yasushi, Ogawa, Yuji, Imajo, Kento, Yoneda, Masato, Kobayashi, Noritoshi, Saito, Satoru, Nakajima, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277396/
https://www.ncbi.nlm.nih.gov/pubmed/35820743
http://dx.doi.org/10.1136/bmjopen-2021-060335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277396/
https://www.ncbi.nlm.nih.gov/pubmed/35820743
http://dx.doi.org/10.1136/bmjopen-2021-060335

Ejemplares similares